SEARCH

SEARCH BY CITATION

References

  • 1
    Hedlund H, Andersson K-E, Ek A. Effects of prazosin in patients with benign prostatic obstruction. J. Urol. 1983; 130: 275 8.
  • 2
    Yamaguchi O, Siraiwa Y, Kobayashi M et al. Clinical evaluation of prazosin hydrochloride on urinary obstruction caused by benign prostatic hypertrophy. Double blind comparative study compared with Paraprost. (Author’s translation) Igaku Yakugaku 1988; 19: 411 29 (in Japanese).
  • 3
    Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H, YM617 Clinical Study Group. Use of an α1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J. Urol. 1990; 144: 908 12.
  • 4
    Kumamoto Y, Tsukamoto T, Yachiku S et al. Clinical evaluation of terazosin hydrochloride on urinary obstruction caused by benign prostatc hypertrophy (II): Double-blind comparative study compared with placebo. Jpn J. Urol. Surg. 1992; 5: 923 840 (in Japanese).
  • 5
    Kawabe K, Tsuchida S, Shimazaki J, Morita T, Yasuda K, Kageyama S. Effect of urapidil on benign prostatic hypertrophy: A multicenter, double-blind study. Urol. Int. 1993; 50: 27 32.
  • 6
    Yamaguchi O, Fukaya Y, Shiraiwa Y et al. Clinical evaluation of naftopidil (KT-611) on urinary obstruction caused by benign prostatic hypertrophy. Double blind comparative study compared with prazosin hydrochloride. Rinsho-Iyaku 1992; 8: 699 722 (in Japanese).
  • 7
    Mebust WK, Bosch R, Donovan J, Okada K, O’Leary MA, Villers A. Symptom evaluation, quality of life and sexuality. In: Cockett ATK, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S, Murphy G (eds). The 2nd International Consultation of Benign Prostatic Hyperplasia. Pitie Salapatiere, Paris, 1993; 13 7.
  • 8
    Homma Y, Kawabe K, Tsukamoto T et al. Estimate criteria for efficacy of treatment in benign prostatic hyperplasia. Int. J. Urol. 1996; 3: 267 73.
  • 9
    Buzelin JM, Hebert M, Blondin P. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: Comparative study with prazosin. Br. J. Urol. 1993; 72: 922 7.
  • 10
    Lepor H, Auerbach S, Puras-Baez A et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J. Urol. 1992; 148: 1467 74.
  • 11
    Abrams P, Speakman M, Stott M, Arkell D, Pocock R. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha-1A adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br. J. Urol. 1997; 80: 587 96.
  • 12
    Lee E & Lee C. Clinical comparison of selective and non-selective α1A-adrenoreceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br. J. Urol. 1997; 80: 606 11.
  • 13
    Jensen DJr. Uninhibited neurogenic bladder treated with prazosin. Scand. J. Urol. Nephrol. 1981; 15: 229 33.
  • 14
    Hieble JP, Bylund DB, Clarke DE et al. International Union of Pharmacology X. Recommendation for nomenclature of alpha1-adrenoceptors: Consensus update. Pharmacol. Rev. 1995; 47: 267 70.
  • 15
    Anderson KE, Lepor H, Wyllie M. Prostatic alpha1-adrenoceptors and uroselectivity. Prostate 1997; 30: 202 15.
  • 16
    Kaplan SA & Kaplan NM. Alpha-blockade: Monotherapy for hypertension and benign prostatic hyperplasia. Urology 1996; 48: 541 50.
  • 17
    De Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur. Urol. 1998; 33: 481 8.